# US 2025/0375543 A1 · Oligonucleotide-based therapeutics and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375543 A1
- Document ID: US20250375543A1
- Status: Published application
- Kind: A1
- Application number: 19/216,566
- Filed: 2025-05-22
- Published: 2025-12-11
- Earliest claimed: 2020-10-30
- Inventors: Tod Speer
- Web page: https://patentgrep.com/patent/US20250375543A1

## CPC

- A61K 51/0491: {Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers}
- A61K 51/0497: {conjugates with a carrier being an organic compounds}
- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61P 35/00: Antineoplastic agents
- C07B 59/005: {Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids}
- C07H 21/04: with deoxyribosyl as saccharide radical
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

Described herein are compounds that are useful for delivering therapeutic, diagnostic, and imaging agents. Also described herein are pharmaceutical compositions containing such compounds and methods of using the compounds and compositions. Also described are processes for manufacture of the compounds and the compositions containing them.

## Claims

### Claim 1

A compound of the Formula (V):
or a pharmaceutically acceptable salt thereof,
wherein:
X2 is a chelating agent-selected from EDTA, DTPA, DOTA, TETA, NOTA, Cyclam, PCBA, DADT, and MAMA;
L1 is a linker group;
L5 is a linker group or a bond, wherein L1 and L5 can be the same or different, wherein L1 and/or L5 has a chain length of from 1 to 40 atoms;
T is a click-chemistry-derived core;
G1 is a single-stranded nucleotide sequence for binding a forward primer;
Q is a randomized single-stranded DNA;
G2 is a single-stranded nucleotide sequence for binding a reverse primer wherein the click-chemistry-derived core is (i) a triazole, (ii) an oxazole, (iii) a heterocycle derivable from electrocyclization chemistry, or (iv) selected from one of the following formula:
wherein Rb is H, alkyl, arylalkyl, -alkyl-S-alkyl or arylalkyl or the side-chain of any naturally- or non-naturally occurring amino acid; and
wherein the compound of the formula (V) is internalized into at least one of the cytoplasm and the nucleus of cancer cells.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the chelating agent is DTPA, DOTA, TETA, or NOTA.

### Claim 3 (depends on 1)

The compound of claim 1, further comprising at least one of a radioactive isotope and a non-radioactive isotope chelated to the chelating agent.

### Claim 4 (depends on 1)

The compound of claim 1, wherein the randomized single-stranded DNA has 10 to 100 nucleotides.

### Claim 5 (depends on 1)

The compound of claim 1, wherein -G1-Q-G2- is a single-stranded DNA sequence -TGCGTGTGTAGTGTGTCTG-Q-CTCTTAGGGATTTGGGGGG- (SEQ ID NO:21), wherein optionally comprises at least one bonding arrangement that renders at least one of G1, Q, and G2 nuclease resistant.

### Claim 6 (depends on 1)

The compound of claim 1, wherein at least one of L1 and L5 is (i) a click chemistry-derived linker, wherein at least one of L1 and L5 is derivable from copper-catalyzed azide-alkyne cycloaddition (CuAAC), strain-promoted azide-alkyne cycloaddition (SPAAC), inverse electron demand Diels-Alder reaction, (IEDDA), and Staudinger ligation (SL); or (ii) a releasable group, optionally wherein the linker group is photochemically-, chemically- or enzymatically cleavable group.

### Claim 7 (depends on 1)

The compound of claim 1, wherein at least one of L1 and L5 is a releasable group.

### Claim 8 (depends on 1)

The compound of claims 1, wherein at least one of G1, Q, and G2 comprises at least one bonding arrangement that renders at least one of G1, Q, and G2 nuclease resistant.

### Claim 9 (depends on 1)

The compound of claim 1, further comprising a at least one of a cell penetrating peptide (CPP) and a nuclear localization sequence (NLS).

### Claim 10 (depends on 1)

The compound of claim 1, wherein the NLS comprises the amino acid sequence PKKKRKV (SEQ ID NO:1).

### Claim 11 (depends on 9)

The compound of claim 9, wherein the CPP comprises the amino acid sequence RRRRRRRR (SEQ ID NO:5).

### Claim 12 (depends on 1)

The compound of claim 1, wherein the compound is a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein.

### Claim 13 (depends on 12)

The compound of claim 12, wherein the compound is a compound of the formula:
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

The compound of claim 1, wherein the compound is a compound of the formula:
or a pharmaceutically acceptable salt thereof;
wherein g is an integer such that the number average molecular weight (Mn) of the —OCH2CH2— moiety is from about 500 g/mol to about 10,000 g/mol.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising one or more compounds of claim 1 and a pharmaceutically acceptable carrier or excipient.

### Claim 16 (depends on 1)

A method of treating cancer in a subject in need of such treatment, comprising administering a therapeutically-effective amount of one or more compounds of claim 1.

### Claim 17 (depends on 16)

The method of claim 16, wherein the cancer is selected from prostate cancer, breast cancer, pancreatic cancer, thyroid cancer, bone cancer, glioblastoma, and neuroendocrine tumors.

### Claim 18 (depends on 1, 16)

The method of claim 16, further comprising administering one or more of compounds of claim 1 in combination with at least one anticancer agent.

### Claim 19 (depends on 1)

The compound of claim 1, wherein the chelating agent is DOTA.

### Claim 20 (depends on 1)

The compound of claim 1, wherein Q comprises the sequence:
(SEQ ID NO: 22)
TCGGGATCAACCCGAGTTCACGCAACT;
(SEQ ID NO: 23)
ACACTAGTACAGTCAGTACGCACGA;
(SEQ ID NO: 24)
TTTTGCGCCTGAAGCCTCCCCAGGA;
(SEQ ID NO: 25)
GTCCGTATCTTGGTCGAAGATGTAC;
(SEQ ID NO: 26)
AGGTTCAATCTACCTTCTGCCATGC;
(SEQ ID NO: 27)
CTGGAATTCCAAATATGCCGGCGAG;
(SEQ ID NO: 28)
ATCGTTCTGGGATACAAGCTTTTGA;
(SEQ ID NO: 29)
AAATATACATTATTCCCATCAAAAT;
(SEQ ID NO: 30)
GGACAAAAAGTCTGAGTCTGACCTT;
(SEQ ID NO: 31)
GATGGCAGTATAGTCGTCATGAGTC;
(SEQ ID NO: 32)
TCGGGATCAACCCGAGTTCACGCAA;
(SEQ ID NO: 33)
ACTCTTTCTGTCACAAGATCTGCAT;
(SEQ ID NO: 34)
AATGTGGATGGCATAGTGGCGGCGC;
(SEQ ID NO: 35)
TACAACCTAGAGGATGAGCTCACGA;
(SEQ ID NO: 36)
TTAGTGTTACATCACATCTCGAGCT;
(SEQ ID NO: 37)
TAGGAGGCATTCATTTTTAAGGTAG;
(SEQ ID NO: 38)
GTTACCACATCGATCTGCGAAAACT;
(SEQ ID NO: 39)
CACCAGTGGTTTGATATACGGCCTA;
(SEQ ID NO: 40)
TAGGTTGTGGTTCCCGAATCGTGAG;
(SEQ ID NO: 41)
GCAACTTGGCTTCCGTCTAAACAAA;
(SEQ ID NO: 42)
GCTATCCTTCTTTTAGCAGACAGTA;
(SEQ ID NO: 43)
TACTCGTCGCGTTTTATTTTTTTGC;
(SEQ ID NO: 44)
ATAAGCCCCCAGCTACTCCCGTTTT;
(SEQ ID NO: 45)
CTTCATGTAGCAACTCATTGTGAAG;
(SEQ ID NO: 46)
TCCCAAAATCTCGCCCCCCGGAATA;
(SEQ ID NO: 47)
AGTTGCCACAAAAATTTACTAAGTC;
(SEQ ID NO: 48)
CAGCTACATTCATTATTTGTTTCCG;
(SEQ ID NO: 49)
TCATACGGAACCTCAGCCCATGACA;
(SEQ ID NO: 50)
CACTTATTAGAAATGCATACCTATA;
(SEQ ID NO: 51)
GTCTGAAATTAATTGATCGTCATGC;
(SEQ ID NO: 52)
GCATCCGATTCACACACTCGCTCAC;
(SEQ ID NO: 53)
CATAACAGATGTTAAATTAGCGTAA;
(SEQ ID NO: 54)
AAAATCATGAGTGGTTTACCGGTAG;
(SEQ ID NO: 55)
CAACCCGCAAAAAGTCTCAGGAGTA;
(SEQ ID NO: 56)
CAGCTTCGCCATCCCTACGGGTAAG;
(SEQ ID NO: 57)
TTCTGCATGGCGGGTATACTCACTA;
(SEQ ID NO: 58)
CCCGTAGCCAAGGAGCCTATACAAC;
(SEQ ID NO: 59)
TTTAAGTTTCCGAATCCAACGTAAA;
(SEQ ID NO: 60)
GGGGAGCAGCAGCGATTTGACCTAG;
(SEQ ID NO: 61)
GAACCAAAGCGCTGCTTCCCATAAA;
(SEQ ID NO: 62)
ATGGTTATCTTACCCTACCAAAGGA;
(SEQ ID NO: 63)
GACCGGGTTCATTTAACCGTACGGG;
(SEQ ID NO: 64)
CTCCAACGCAGTAGCCAGGTACACA;
(SEQ ID NO: 65)
TAACTGTTGCCTCTCACATGGTCAA;
(SEQ ID NO: 66)
CGCTTAAGTGGTATAGTCTCCATCG;
(SEQ ID NO: 67)
TCGCACCCTATCATAGTCCGACACC;
(SEQ ID NO: 68)
GAATCTAAACGTTAGCAATCGGCGT;
(SEQ ID NO: 69)
CGGTTCCAGGTGGGCCCGTATACGT;
(SEQ ID NO: 70)
AGCTCCCCCCCGCGTTATACCTGAC;
(SEQ ID NO: 71)
GCCTAGCATCCAATCGACGTACCGC;
(SEQ ID NO: 72)
CACAACTTCCATATGTCAGTTCAAC;
(SEQ ID NO: 73)
AAGCAGTCTCATTCATCCATCACTA;
(SEQ ID NO: 74)
GCTTGGATTTAAACCAAGCGTCCCG;
(SEQ ID NO: 75)
TAGATATCGTATAATATGGGGATAA;
(SEQ ID NO: 76)
TAATGCCACACGTTATGTCTCCCAA;
(SEQ ID NO: 77)
ACGAAGGCGGCATGGTAATCTGCAC;
(SEQ ID NO: 78)
GGCGTGGGTTGACCGGATACATGAA;
(SEQ ID NO: 79)
TACAAGACCGAACCTGGTTTATACC;
(SEQ ID NO: 80)
GTGGACTCGACATCCGACAGTCAGT;
(SEQ ID NO: 81)
TAACCGGTTGGATAGCGATTCGATT;
(SEQ ID NO: 82)
GCCAGTCTAACAGTAATTATGCAAA;
(SEQ ID NO: 83)
TATTCATAATACATGAGATGGCACG;
(SEQ ID NO: 84)
CATAGGATTCGTAATGTATAAGTGT;
(SEQ ID NO: 85)
TATCTCAGAATACCGCACTCACGTG;
(SEQ ID NO: 86)
CGGTCAAAGCACCTGGAGCGTATTC;
(SEQ ID NO: 87)
CTGTACTTGATCCAAGGTTTGAAGG;
(SEQ ID NO: 88)
GACTACGTCGCTTGCAAATCATCCG;
(SEQ ID NO: 89)
TGTAGTCTATAACTCCCTGGCGCAG;
(SEQ ID NO: 90)
GGTAGGCAGCACGTTTGTGTGAACC;
(SEQ ID NO: 91)
CTCTTCACCATTTTATCGCCATGCA;
(SEQ ID NO: 92)
GTCTGTCTGTATCATCCGAGCGACA;
(SEQ ID NO: 93)
GGAAGCGGGATATATGGTGCCGTCC;
(SEQ ID NO: 94)
TAACTCAGACAGCTAGCTATCGTTA;
(SEQ ID NO: 95)
TAACTCTGCATTGCTCTCAGGGAGC;
(SEQ ID NO: 96)
GTGTCTTGTACTCTGACCTGAAGCG;
(SEQ ID NO: 97)
GGAATAAGAAGTCTTAGTAGCCCAC;
(SEQ ID NO: 98)
AAATAGTAAATTGAGGAGCCGTTTA;
(SEQ ID NO: 99)
CTACGTATAAACGGTTGGTTAGGTT;
(SEQ ID NO: 100)
AGCATGAATGGAGGCCGTTAACAAA;
(SEQ ID NO: 101)
TCCCGCAGTTATCGCGGCTGTCTCA;
(SEQ ID NO: 102)
CGCCGTAGGGCGTATGGCGCGTCTG;
(SEQ ID NO: 103)
CTACGTGCCAGTTTATACCCCGGAA;
(SEQ ID NO: 104)
CCGCTAGAGAACCTTGATGATTCTG;
(SEQ ID NO: 105)
TATCTTAAGTCAGTGGGGCTCGTCG;
(SEQ ID NO: 106)
TTTATGAAGAGCACATCATAAGAAG;
(SEQ ID NO: 107)
TGGCCGCCTAGAGTTAAGAACTATT;
(SEQ ID NO: 108)
GGGTCGAATCTAGTTTTGTAACAGG;
(SEQ ID NO: 109)
TGACAGTGGCGTCACCCGTTCACCC;
(SEQ ID NO: 110)
CTGCGTACTGGATATGTAAAAGATG;
(SEQ ID NO: 111)
GGAATGCGTGCAGACCCGTTGGTTT;
(SEQ ID NO: 112)
GTACCCAAATGTGAGTGACGCCATT;
(SEQ ID NO: 113)
CATCTCTGTGTACGGAAATCTTTGA;
(SEQ ID NO: 114)
GTTTAGCGATCCTTTTGAGCATTAG;
(SEQ ID NO: 115)
CTAAGTTGTAAGCGCAGCACAGCGT;
(SEQ ID NO: 116)
GAAACCTTTGTGCAACGCTCGTGTT;
(SEQ ID NO: 117)
CTTGTCTGTCCCGCTAGTTTGGGGG;
(SEQ ID NO: 118)
CTAAAACCGGGCGTAGACGATGGTC;
(SEQ ID NO: 119)
CGGTAGTCGCCGGCTTATATGCCGA;
(SEQ ID NO: 120)
TTCTGATATCTGATGTTTTATGGCT;
(SEQ ID NO: 121)
AGCTCGTCTAGAAACCGTGGGCCAA;
(SEQ ID NO: 122)
GATAAGGGTAGAGTCCAGTGAACGG;
or
wherein:
G1-Q-G2 comprises the sequence:
(SEQ ID NO: 123)
TGCGTGTGTAGTGTGTCTGTCGGGATCAACCCGAGTTCACGCAACTCTTA
GGGATTTGGGCGG;
(SEQ ID NO: 124)
TGCGTGTGTAGTGTGTCTGGACCGGGTTCATTTAACCGTACGGGCTCTTA
GGGATTTGGGCGG;
(SEQ ID NO: 125)
TGCGTGTGTAGTGTGTCTGGCTTGGATTTAAACCAAGCGTCCCGCTCTTA
GGGATTTGGGCGG;
or
(SEQ ID NO: 126)
TGCGTGTGTAGTGTGTCTGCGGTAGTCGCCGGCTTATATGCCGACTCTTA
GGGATTTGGGCGG.
